

CARTA CIRCULAR # M1912128

30 de diciembre de 2019

A TODOS LOS LABORATORIOS CLINICOS PARTICIPANTES DE TRIPLE-S SALUD, INC. (EN ADELANTE TRIPLE-S)

Re: Códigos nuevos CPT® 2020- Negocio comercial y Programa de Cuidado Integrado (CCI)

Triple-S cumpliendo con el compromiso de mantener a nuestros laboratorios clínicos informados le incluimos la lista de códigos nuevos publicados en el *Current Procedure Terminology* (CPT®) para el 2020, con sus respectivas tarifas. Favor referirse al CPT® 2020 para la descripción completa de los mismos.

El rango relacionado con pruebas genéticas (CPT 81105 al 81599) requieren ser pre-autorizados y necesitan ser ordenados por ciertas especialidades médicas según especificado en cartas circulares previas. (#M1607090 y #M1606070)

Los códigos marcados con \$0.00 no están cubiertos en ninguna de nuestras pólizas.

Estos códigos entrarán en vigor para servicios prestados a partir del **1 de enero de 2020**.

Estas tarifas no aplican a los asegurados del Programa de Medicare Advantage.

Esta Carta Circular contiene cambios que podrían constituir enmiendas a su contrato de proveedor participante con Triple-S Salud, Inc. Usted tendrá 30 días a partir de la fecha de la Carta Circular para presentar por escrito cualquier objeción a los cambios aquí notificados. De objetarse en todo o en parte los cambios en la Carta Circular se entenderán objetados en su totalidad. Deberá dirigir su objeción vía correo electrónico a disputasadministrativas@ssspr.com o por correo postal:

DISPUTAS ADMINISTRATIVAS - ADMINISTRACIÓN DE LA RED


Triple-S Salud, Inc.
PO Box 363628
San Juan PR 00936-3628

Una vez transcurrido el plazo de 30 días antes indicado sin que se haya recibido una objeción a los cambios en la presente Carta Circular, se entenderá que ha consentido a los mismos, los cambios entrarán en vigor y las partes estarán obligadas al cumplimiento de éstos.

#COMPROV_2019_086_S

Si necesita información adicional o tiene alguna pregunta, comuníquese con nuestro Centro de Servicio al Proveedor al 787-749-4700 o al 1-877-357-9777 (libre de cargos para llamadas de larga distancia). Nuestro Centro de Llamadas está disponible de lunes a viernes de 7:30 a.m. a 8:00 p.m. y sábados de 8:00 a.m. a 12:00 p.m. – AST (tiempo estándar del Atlántico).

Cordialmente,



Benjamín Santiago, MD
Vicepresidente
División de Manejo Médico
Triple-S Salud, Inc.



Dionnel Pérez Morales
Vicepresidente
División de Administración de la Red
Triple-S Salud, Inc.

Si aún no se ha registrado para recibir las Cartas Circulares por medio electrónico, acceda nuestra página de Internet www.ssspr.com, regístrese y únase a Triple-S Salud en la conservación del ambiente.

#COMPROV_2019_086_S

Therapeutic Drug Assays		
CPT 2020	Fee	Comments
80145	\$0.00	Monoclonal antibody (immunosuppressive) used to treat autoimmune conditions (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and others)
80187	\$0.00	This procedure is used to Antifungal Medication
80230	\$0.00	Monoclonal antibody (immunosuppressive) used to treat autoimmune conditions (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and others)
80235	\$0.00	This procedure is used to Epilepsy Treatment
80280	\$0.00	Monoclonal antibody (immunosuppressive) used to treat autoimmune conditions (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and others)
80285	\$0.00	This procedure is used to Epilepsy Treatment

Tier 1 Molecular Pathology Procedures		
CPT 2020	Fee	Comments
81277	\$1189.00	This procedure describes cytogenomic neoplasia. Neoplasia cytogenomic microarray analysis, also known as neoplasia chromosomal microarray analysis (CMA), is increasingly relevant in establishing a diagnosis and prognosis for people with cancer. With a single test, CMA detects chromosome deletions, chromosome duplications and amplifications, and copy neutral loss of heterozygosity (LOH) across the entire genome.
81307	\$290.00	
81308	\$309.00	
81309	\$282.00	

Multianalyte Assays with Algorithmic Analyses		
CPT 2020	Fee	Comments
81522	\$3970.00	Gene expression profiling tests analyze a number of different genes within your cancer cells to predict your risk of cancer recurrence.
81542	\$0.00	This procedure has the Triple-S policy 11.003.051. The policy is investigative. Please refer to the Triple-S portal for the corresponding Medical Policy
81552	\$3873.00	Uveal Melanoma is associated with a high rate of metastatic disease, and survival after the development of metastatic disease is poor. Prognosis following treatment of local disease can be assessed using various factors, including clinical and demographic markers, tumor stage, tumor characteristics and tumor cytogenetics. Gene expression profiling (GEP) is being utilized to determine prognosis.

Microbiology		
CPT 2020	Fee	Comments
87563	\$25.00	This code was established to specifically code the amplified probe for <i>Mycoplasma genitalium</i> . <i>Mycoplasma genitalium</i> is now recognized as an important cause for urethritis and cervicitis with symptoms difficult to distinguish from gonorrhea and chlamydia. Hologic recently received FDA approval for their Aptima® assay. This service was previously reported using unlisted amplified probe technique code 87798.

Proprietary Laboratory Analyses*			
CPT 2020		Fee	Comments
0062u	0101u	\$0.00	<p>These codes are not required to fulfill the Category I criteria. The standards for inclusion in this section are:</p> <ul style="list-style-type: none"> The test must be commercially available in the United States for use on human specimens. The clinical laboratory or manufacturer that offers the test must request the code when a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence. <p>The service should not be reported with any other CPT code(s), and other CPT code(s) should not be used to report services that may be reported with that specific PLA code.</p>
0063u	0102u		
0064u	0103u		
0065u	0104u		
0066u	0105u		
0067u	0106u		
0068u	0107u		
0069u	0108u		
0070u	0109u		
0071u	0110u		
0072u	0111u		
0073u	0112u		
0074u	0113u		
0075u	0114u		
0076u	0115u		
0077u	0116u		
0078u	0117u		
0079u	0118u		
0080u	0119u		
0081u	0120u		
0082u	0121u		
0083u	0122u		
0084u	0123u		
0085u	0124u		
0086u	0125u		
0087u	0126u		
0088u	0127u		
0089u	0128u		
0090u	0129u		
0091u	0130u		
0092u	0131u		
0093u	0132u		
0094u	0133u		
0095u	0134u		
0096u	0135u		
0097u	0136u		
0098u	0137u		
0099u	0138u		
0100u			

*\$0.00 – Códigos no cubiertos como procedimiento nuevo

CIRCULAR LETTER # M1912128

December 30, 2019

**TO ALL IN-NETWORK CLINICAL LABORATORIES OF TRIPLE-S SALUD, INC.
(TRIPLE-S)**

Re: New CPT® 2020 CODES – Commercial plan and Integrated Care Centers (CCI by spanish acronym)

Triple-S complying with the commitment to keep our clinical laboratories informed, we include a list of new codes, published in the Current Procedure Terminology (CPT®) for 2020, with corresponding fees. Please refer to CPT® 2020 for complete description

The range related to genetic testing (CPT 81105 to 81599) needs to be pre-authorized and need to be ordered by a specific medical specialty. (Circular Letters #M1607090 and #M1606070).

Those codes marked with \$0.00 are not covered under any of our policies.

These codes will be effective for services rendered starting **January 1st, 2020**

These fees are not applicable to Medicare Advantage beneficiaries, or VITAL Plan.

This Circular Letter contains changes that may constitute amendments to your participating provider contract with Triple-S Salud, Inc. You will have 30 days from the date of the Circular Letter to submit in writing any objection to the changes notified herein. If changes in the Circular Letter are objected to in whole or in part, they shall be deemed to be objected to in their entirety. You should direct your objection to disputasadministrativas@ssspr.com or:


DISPUTAS ADMINISTRATIVAS - ADMINISTRACIÓN DE LA RED

Triple-S Salud, Inc.
PO Box 363628
San Juan PR 00936-3628

Once the 30-day period indicated above has elapsed without receipt of an objection to the changes in this Circular Letter, it will be understood that you have agreed to them, the changes will become effective and the parties will be bound by them.

Should you need additional information or have any question, please contact our Provider Service Center at 787-749-4700 or 1-877-357-9777 (For long distance calls, free of charge). Our Call Center is available from Monday to Friday from 7:30 a.m. to 8:00 p.m. and Saturdays from 8:00 a.m. to 12:00 p.m.

Cordially,



Benjamín Santiago, MD
Vice President
Medical Management Division
Triple-S Salud, Inc.



Dionnel Pérez Morales
Vice President
Network Management Division
Triple- S Salud, Inc.

If you have not yet registered to receive the Circular Letters electronically, access our website www.ssspr.com, register and join Triple-S Salud in environmental conservation.

#COMPROV_2019_086_E

Therapeutic Drug Assays		
CPT 2020	Fee	Comments
80145	\$0.00	Monoclonal antibody (immunosuppressive) used to treat autoimmune conditions (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and others)
80187	\$0.00	This procedure is used to Antifungal Medication
80230	\$0.00	Monoclonal antibody (immunosuppressive) used to treat autoimmune conditions (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and others)
80235	\$0.00	This procedure is used to Epilepsy Treatment
80280	\$0.00	Monoclonal antibody (immunosuppressive) used to treat autoimmune conditions (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and others)
80285	\$0.00	This procedure is used to Epilepsy Treatment

Tier 1 Molecular Pathology Procedures		
CPT 2020	Fee	Comments
81277	\$1189.00	This procedure describes cytogenomic neoplasia. Neoplasia cytogenomic microarray analysis, also known as neoplasia chromosomal microarray analysis (CMA), is increasingly relevant in establishing a diagnosis and prognosis for people with cancer. With a single test, CMA detects chromosome deletions, chromosome duplications and amplifications, and copy neutral loss of heterozygosity (LOH) across the entire genome.
81307	\$290.00	
81308	\$309.00	
81309	\$282.00	

Multianalyte Assays with Algorithmic Analyses		
CPT 2020	Fee	Comments
81522	\$3970.00	Gene expression profiling tests analyze a number of different genes within your cancer cells to predict your risk of cancer recurrence.
81542	\$0.00	This procedure has the Triple-S policy 11.003.051. The policy is investigative. Please refer to the Triple-S portal for the corresponding Medical Policy
81552	\$3873.00	Uveal Melanoma is associated with a high rate of metastatic disease, and survival after the development of metastatic disease is poor. Prognosis following treatment of local disease can be assessed using various factors, including clinical and demographic markers, tumor stage, tumor characteristics and tumor cytogenetics. Gene expression profiling (GEP) is being utilized to determine prognosis.

Microbiology		
CPT 2020	Fee	Comments
87563	\$25.00	This code was established to specifically code the amplified probe for <i>Mycoplasma genitalium</i> . <i>Mycoplasma genitalium</i> is now recognized as an important cause for urethritis and cervicitis with symptoms difficult to distinguish from gonorrhea and chlamydia. Hologic recently received FDA approval for their Aptima® assay. This service was previously reported using unlisted amplified probe technique code 87798.

Proprietary Laboratory Analyses*			
CPT 2020		Fee	Comments
0062u	0101u	\$0.00	<p>These codes are not required to fulfill the Category I criteria. The standards for inclusion in this section are:</p> <ul style="list-style-type: none"> The test must be commercially available in the United States for use on human specimens. The clinical laboratory or manufacturer that offers the test must request the code when a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence. <p>The service should not be reported with any other CPT code(s), and other CPT code(s) should not be used to report services that may be reported with that specific PLA code.</p>
0063u	0102u		
0064u	0103u		
0065u	0104u		
0066u	0105u		
0067u	0106u		
0068u	0107u		
0069u	0108u		
0070u	0109u		
0071u	0110u		
0072u	0111u		
0073u	0112u		
0074u	0113u		
0075u	0114u		
0076u	0115u		
0077u	0116u		
0078u	0117u		
0079u	0118u		
0080u	0119u		
0081u	0120u		
0082u	0121u		
0083u	0122u		
0084u	0123u		
0085u	0124u		
0086u	0125u		
0087u	0126u		
0088u	0127u		
0089u	0128u		
0090u	0129u		
0091u	0130u		
0092u	0131u		
0093u	0132u		
0094u	0133u		
0095u	0134u		
0096u	0135u		
0097u	0136u		
0098u	0137u		
0099u	0138u		
0100u			

*Those marked with \$0.00 are not covered under any of our policies.